AU2016279096B2 - Composition containing carboplatin and use - Google Patents

Composition containing carboplatin and use Download PDF

Info

Publication number
AU2016279096B2
AU2016279096B2 AU2016279096A AU2016279096A AU2016279096B2 AU 2016279096 B2 AU2016279096 B2 AU 2016279096B2 AU 2016279096 A AU2016279096 A AU 2016279096A AU 2016279096 A AU2016279096 A AU 2016279096A AU 2016279096 B2 AU2016279096 B2 AU 2016279096B2
Authority
AU
Australia
Prior art keywords
dcp
leukemia
subject
pharmaceutical composition
body weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016279096A
Other languages
English (en)
Other versions
AU2016279096A1 (en
Inventor
Xiaozhong Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syn Nat Products Enterprise LLC
Original Assignee
Syn Nat Products Enterprise LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syn Nat Products Enterprise LLC filed Critical Syn Nat Products Enterprise LLC
Publication of AU2016279096A1 publication Critical patent/AU2016279096A1/en
Application granted granted Critical
Publication of AU2016279096B2 publication Critical patent/AU2016279096B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2016279096A 2015-06-19 2016-06-20 Composition containing carboplatin and use Ceased AU2016279096B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562182124P 2015-06-19 2015-06-19
US62/182,124 2015-06-19
PCT/US2016/038333 WO2016205782A1 (en) 2015-06-19 2016-06-20 Composition containing carboplatin and use

Publications (2)

Publication Number Publication Date
AU2016279096A1 AU2016279096A1 (en) 2018-01-04
AU2016279096B2 true AU2016279096B2 (en) 2021-01-07

Family

ID=57546650

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016279096A Ceased AU2016279096B2 (en) 2015-06-19 2016-06-20 Composition containing carboplatin and use

Country Status (9)

Country Link
US (1) US10980768B2 (cg-RX-API-DMAC7.html)
EP (1) EP3297440A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018517759A (cg-RX-API-DMAC7.html)
KR (1) KR20180014834A (cg-RX-API-DMAC7.html)
CN (1) CN108697093A (cg-RX-API-DMAC7.html)
AU (1) AU2016279096B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017027277A2 (cg-RX-API-DMAC7.html)
CA (1) CA2988989A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016205782A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017024727A2 (pt) 2015-05-18 2018-07-31 Syn Nat Products Entpr Llc cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal
BR112017027277A2 (pt) 2015-06-19 2018-09-04 Syn Nat Products Entpr Llc ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
AU2016279099B2 (en) 2015-06-19 2021-09-23 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
CN107847521A (zh) 2015-06-25 2018-03-27 新纳特产品公司 药物共晶组合物及其用途
AU2018372753B2 (en) * 2017-11-21 2024-03-21 Medoncare Pharmaceutical Co., Ltd Combination product comprising dicycloplatin and preparation method and use thereof
CN108884119A (zh) * 2018-02-22 2018-11-23 昆明贵研药业有限公司 一种双二羧酸二氨络铂(ii)衍生物的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1186610A1 (en) * 2000-03-03 2002-03-13 Yang, Xuqing Dicarboxylato diammine platinum derivatives and compositions comprising them as anti-tumor agents

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922689A (en) 1995-09-11 1999-07-13 Unitech Pharmaceuticals, Inc. Cisplatin analogs for cancer treatment
US6297245B1 (en) 1998-08-04 2001-10-02 Unitech Pharmaceuticals Cisplatin and folic acid administered to treat breast cancer
KR100317473B1 (ko) 1999-05-11 2001-12-22 이계호 신규의 백금(ｉｖ)착제 및 그 제조방법
CN1314357A (zh) * 2000-03-16 2001-09-26 杨旭清 双环酸铂抗癌药
AUPQ641100A0 (en) 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
JP2004532260A (ja) 2001-05-31 2004-10-21 ザ チャイニーズ ユニバーシティ オブ ホンコン デメチルカンタリジンをプラチナ含有抗がん剤と組み合わせて含む組成物およびその用途
US7259270B2 (en) 2001-11-30 2007-08-21 Jingzun Wang Supermolecular carboplatin derivatives, their preparation and pharmaceutical composition containing them as active ingredient and applications of the compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
GEP20074134B (en) 2002-08-19 2007-06-25 Pfizer Prod Inc Combination therapy for hyperproliferative diseases
WO2005016946A2 (en) 2003-08-13 2005-02-24 University Of South Florida Platinum complexes for the treatment of tumors
DE602004025726D1 (de) * 2003-11-14 2010-04-08 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
MX2007008810A (es) 2005-01-21 2007-11-21 Astex Therapeutics Ltd Compuestos farmaceuticos.
CN100391437C (zh) * 2005-09-12 2008-06-04 重庆医科大学附属第二医院 抗急性髓性白血病的gm-csf靶向药物脂质体及制备方法
BRPI0708004A2 (pt) 2006-01-30 2011-05-17 Platco Technologies Proprietary Ltd preparação de complexos de platina (ii)
CN1857221A (zh) * 2006-04-14 2006-11-08 济南帅华医药科技有限公司 一种同载铂类化合物及其增效剂的抗癌缓释剂
ES2556677T3 (es) * 2006-08-02 2016-01-19 Sunesis Pharmaceuticals, Inc. Utilización combinada de ácido (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxílico y citarabina (Ara-C) para el tratamiento de la leucemia
NZ591394A (en) * 2008-09-15 2013-03-28 Kasina Laila Innova Pharmaceuticals Private Ltd Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
CZ302618B6 (cs) 2009-09-10 2011-08-03 Univerzita Palackého Cyklobutan-1,1-dikarboxylátokomplexy platiny s deriváty N6-benzyladeninu, zpusoby jejich prípravy a použití techto komplexu jako léciv v protinádorové terapii
US20110287110A1 (en) * 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
JP6091431B2 (ja) * 2011-01-31 2017-03-15 ルコラス−エム．ディー．リミテッド 医薬的使用
CN102924528B (zh) * 2012-10-29 2015-04-15 东南大学 抗肿瘤二价铂配合物以及该配合物和其配体的制备方法
EP2924044B1 (en) * 2012-11-17 2018-10-31 Beijing Shuobai Pharmaceutical Co., LTD Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
CN103494838B (zh) 2013-09-30 2016-05-11 武汉大学 一种化疗药物组合物
MX361488B (es) 2013-10-17 2018-12-07 Vertex Pharma Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il ) amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteínas cinasa dependientes de adn (adn-pk).
CN111638234B (zh) * 2014-08-13 2024-09-03 北京默加农生物技术发展有限公司 一种以双环铂为有效成分的药物的检测方法
CN104127402B (zh) * 2014-08-15 2019-08-30 北京默加农生物技术发展有限公司 双环铂在制备抗病毒药物和抗菌药物中的应用
CN104693245A (zh) * 2015-03-13 2015-06-10 卓越同达医药科技开发（苏州）有限公司 超分子抗癌药物双环铂的制备方法
KR102432526B1 (ko) 2015-04-10 2022-08-12 신-낫 프로덕츠 엔터프라이즈 엘엘씨 디시클로플라틴의 제조방법
KR102569221B1 (ko) 2015-04-22 2023-08-21 신-낫 프로덕츠 엔터프라이즈 엘엘씨 공결정 조성물 및 그의 약제학적 용도
BR112017024727A2 (pt) 2015-05-18 2018-07-31 Syn Nat Products Entpr Llc cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal
AU2016279099B2 (en) 2015-06-19 2021-09-23 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
BR112017027277A2 (pt) 2015-06-19 2018-09-04 Syn Nat Products Entpr Llc ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
CN107847521A (zh) 2015-06-25 2018-03-27 新纳特产品公司 药物共晶组合物及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1186610A1 (en) * 2000-03-03 2002-03-13 Yang, Xuqing Dicarboxylato diammine platinum derivatives and compositions comprising them as anti-tumor agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LI SU ET AL, "Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2013), Vol. 51, No. 2, pp. 96 - 105 *
YU JJ ET AL, "Dicycloplatin, a Novel Platinum Analog in Chemotherapy: Synthesis of Chinese Pre-clinical and Clinical Profile and Emerging Mechanistic Studies", ANTICANCER RESEARCH,, (2014-01-01), vol. 34, no. 1, pages 455 - 463 *

Also Published As

Publication number Publication date
EP3297440A1 (en) 2018-03-28
CN108697093A (zh) 2018-10-23
BR112017027277A2 (pt) 2018-09-04
US20180169055A1 (en) 2018-06-21
US10980768B2 (en) 2021-04-20
WO2016205782A1 (en) 2016-12-22
EP3297440A4 (en) 2019-04-10
JP2018517759A (ja) 2018-07-05
AU2016279096A1 (en) 2018-01-04
CA2988989A1 (en) 2016-12-22
KR20180014834A (ko) 2018-02-09

Similar Documents

Publication Publication Date Title
AU2016279096B2 (en) Composition containing carboplatin and use
Stathopoulos et al. Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study
EP3750530B1 (en) Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer
Mauer et al. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus
EP3429614B1 (en) Method of treating triple negative breast cancer
WO2010125462A2 (en) Pentamidine combinations for treating cancer
EP2832358A1 (en) Pharmaceutical kit for use in the treatment of colon and colorectal cancer
US9669053B2 (en) Compositions and methods for enhancing the effectiveness of systemic, HIPEC, IP, and related cancer treatments
Franciosi et al. Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients
KR20210013155A (ko) 종양 질환 치료용 약제의 제조에서 egfr 억제제와 조합된 cdk4/6 억제제의 용도
WO2022228323A1 (zh) Ly3009120在制备治疗骨髓增殖性肿瘤的药物中的应用
JP2017507151A (ja) がんの治療のための併用療法としてのエリブリン及びｍＴＯＲ阻害剤の使用
WO2015172712A1 (zh) 维生素c与抗肿瘤药物协同作用的注射用药物组合物
Nghiem et al. Avelumab in patients with previously treated Merkel cell carcinoma (JAVELIN Merkel 200): Updated overall survival data after more than five years of follow up
CN101167741B (zh) 莱菔硫烷和铂类药的抗癌联合制剂
US20190183893A1 (en) Low dose of sildenafil as an antitumor drug
EP3565547B1 (en) Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
WO2020192506A1 (zh) 西奥罗尼用于小细胞肺癌的治疗
KR20160141748A (ko) 항암제 및 부작용 경감제
WO2019155448A1 (en) Methods and combination therapy to treat biliary tract cancer
CN111249274B (zh) 银杏内酯b在制备胶质瘤细胞活性抑制剂中的应用
WO2013169390A1 (en) Zeaxanthin for tumor treatment
JP6243850B2 (ja) 抗がん剤による末梢神経障害の予防、治療、または軽減剤
Saigusa et al. Efficacy and safety of amrubicin in non-small-cell lung cancer patients beyond third-line therapy
RU2784869C1 (ru) Чиаураниб для лечения мелкоклеточного рака легкого

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired